Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Table of Contents

Page standards status: Informative
.. 0 Table of Contents
... 1 Introduction
... 2 Evidence Profiles
... 3 EvidenceVariable Profiles
... 4 Group Profiles
... 5 Citation Profiles
... 6 ArtifactAssessment Profiles
... 7 Composition Profiles
... 8 Other Profiles
... 9 Profiles
... 10 Extensions
... 11 Terminologies
... 12 Examples
... 13 Downloads
... 14 Artifacts Summary
.... 14.1 AbsenceOfExposureDefinition
.... 14.2 Adaptation
.... 14.3 BaselineMeasureEvidence
.... 14.4 BaselineMeasureReport
.... 14.5 BaselineVariablesList
.... 14.6 BookCitation
.... 14.7 BookPartCitation
.... 14.8 CertaintyOfEvidence
.... 14.9 Classification
.... 14.10 CohortDefinition
.... 14.11 Comment
.... 14.12 ComparativeBaselineMeasureEvidence
.... 14.13 ComparativeEvidence
.... 14.14 ComparativeEvidenceReport
.... 14.15 ComparativeEvidenceReportExpanded
.... 14.16 ComparativeEvidenceReportSubject
.... 14.17 ComparativeEvidenceSynthesisReport
.... 14.18 ComparativeParticipantFlowEvidence
.... 14.19 ComparatorGroup
.... 14.20 ComparatorOnlyEvidence
.... 14.21 Comparison
.... 14.22 CompositeRating
.... 14.23 ConceptualCohortDefinition
.... 14.24 ConceptualComparatorDefinition
.... 14.25 ConceptualExposureDefinition
.... 14.26 DatabaseCitation
.... 14.27 DatabaseEntryCitation
.... 14.28 DatasetCitation
.... 14.29 DateAsRating
.... 14.30 DichotomousIntendedOutcome
.... 14.31 EndpointAnalysisPlan
.... 14.32 EvidenceAssessment
.... 14.33 EvidenceList
.... 14.34 EvidenceReport
.... 14.35 EvidenceReportPackage
.... 14.36 EvidenceReportSubject
.... 14.37 EvidenceSynthesisEvidence
.... 14.38 ExposureGroup
.... 14.39 GroupAssignment
.... 14.40 GroupR6
.... 14.41 Guideline
.... 14.42 InterventionOnlyEvidence
.... 14.43 JournalArticleCitation
.... 14.44 M11Report
.... 14.45 MetaanalysisEligibilityCriteria
.... 14.46 MetaanalysisOutcomeDefinition
.... 14.47 MetaanalysisStudyGroup
.... 14.48 NetEffectContribution
.... 14.49 NetEffectContributionList
.... 14.50 NetEffectContributions
.... 14.51 NetEffectEstimate
.... 14.52 NonComparativeEvidence
.... 14.53 OutcomeDefinition
.... 14.54 OutcomeImportance
.... 14.55 OutcomeList
.... 14.56 OutcomeMeasureReport
.... 14.57 OutcomeVariablesList
.... 14.58 ParticipantFlowEvidence
.... 14.59 ParticipantFlowEvidenceVariable
.... 14.60 ParticipantFlowReasonEvidenceVariable
.... 14.61 ParticipantFlowReport
.... 14.62 ParticipantFlowVariablesList
.... 14.63 PreprintCitation
.... 14.64 Rating
.... 14.65 Recommendation
.... 14.66 RecommendationAction
.... 14.67 RecommendationEligibilityCriteria
.... 14.68 RecommendationJustification
.... 14.69 RecommendationPlan
.... 14.70 RecommendationRating
.... 14.71 ResearchStudyDataDictionary
.... 14.72 ResearchStudySupport
.... 14.73 RiskOfBias
.... 14.74 SearchResults
.... 14.75 SearchStrategy
.... 14.76 SingleStudyEvidence
.... 14.77 SoaPlanDefinition
.... 14.78 SoftwareCitation
.... 14.79 StatisticModel
.... 14.80 StudyDesign
.... 14.81 StudyEligibilityCriteria
.... 14.82 StudyGroup
.... 14.83 StudyRegistryRecord
.... 14.84 SummaryOfFindings
.... 14.85 SummaryOfNetEffect
.... 14.86 SystematicReview
.... 14.87 SystematicReviewEligibilityCriteria
.... 14.88 SystematicReviewExcludedStudies
.... 14.89 SystematicReviewIncludedStudies
.... 14.90 VariableDefinition
.... 14.91 WebPageCitation
.... 14.92 ArtifactAssessmentCompared
.... 14.93 ArtifactAssessmentDateAsRating
.... 14.94 ArtifactPublicationStatus
.... 14.95 CharacteristicTiming
.... 14.96 CiteAs
.... 14.97 EvidenceVariableHandlingDetail
.... 14.98 GuidelineRegistration
.... 14.99 NumberAnalyzed
.... 14.100 RelatesTo
.... 14.101 RelatesToClassifier
.... 14.102 RelatesToWithQuotation
.... 14.103 RelativeOutcomeImportance
.... 14.104 ResearchStudyExcludedStudy
.... 14.105 ResearchStudyIncludedStudy
.... 14.106 ResearchStudyIsLowInterventionTrial
.... 14.107 ResearchStudyNumberOfStudiesIdentified
.... 14.108 ResearchStudyNumberOfStudiesIncluded
.... 14.109 ResearchStudySaeReportingMethod
.... 14.110 ResearchStudySearchStrategy
.... 14.111 ResearchStudySponsorConfidentialityStatement
.... 14.112 ResearchStudyStudyAmendment
.... 14.113 ResearchStudySystematicReviewEligibilityCriteria
.... 14.114 StatisticModelExpression
.... 14.115 StatisticModelIncludeIf
.... 14.116 EBMonFHIR Profile Name Value Set
.... 14.117 Evidence Rating System Classifier Codes Value Set
.... 14.118 Recommendation Justification Classifier Codes Value Set
.... 14.119 Research Study Document Types Value Set
.... 14.120 Search Strategy Characteristic Value Set
.... 14.121 EBMonFHIR Profile Name Code System
.... 14.122 Evidence Rating System Classifier Code System
.... 14.123 Research Study Document Types Code System
.... 14.124 Search Strategy Characteristic Code System
.... 14.125 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
.... 14.126 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.127 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
.... 14.128 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
.... 14.129 15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.
.... 14.130 179899
.... 14.131 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.
.... 14.132 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
.... 14.133 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
.... 14.134 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
.... 14.135 19967827 Wonder woman was Argentine and her real name was Evita.
.... 14.136 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
.... 14.137 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
.... 14.138 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
.... 14.139 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
.... 14.140 23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
.... 14.141 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
.... 14.142 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
.... 14.143 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
.... 14.144 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
.... 14.145 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
.... 14.146 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
.... 14.147 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
.... 14.148 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.
.... 14.149 26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
.... 14.150 26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns.
.... 14.151 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.
.... 14.152 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
.... 14.153 27979893 6. Glycemic Targets.
.... 14.154 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.
.... 14.155 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.
.... 14.156 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.
.... 14.157 29357271 Using Hawkeye from the Avengers to communicate on the eye.
.... 14.158 29694275 A regressive formula of perversity: Wertham and the women of comics.
.... 14.159 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics.
.... 14.160 30467172 Finding my inner Wonder Woman.
.... 14.161 30545967 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 14.162 34871555 What Can Wonder Woman Teach Radiologists?
.... 14.163 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
.... 14.164 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.
.... 14.165 367832
.... 14.166 367833
.... 14.167 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
.... 14.168 38584159 Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.
.... 14.169 399870
.... 14.170 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.
.... 14.171 A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus
.... 14.172 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 14.173 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.174 Add-on Amlodipine at 6 weeks
.... 14.175 Adults with diabetes mellitus type 2
.... 14.176 Adults with type 2 diabetes and CVD and CKD
.... 14.177 Adults with type 2 diabetes and established CVD (but no CKD)
.... 14.178 Adverse event free and hypertension control
.... 14.179 Adverse event free and hypertension control at 12 weeks
.... 14.180 Adverse Events Report for NCT03640312
.... 14.181 Age
.... 14.182 Age with comparator
.... 14.183 Age with intervention
.... 14.184 Aircraft Type
.... 14.185 Aircraft Type with comparator
.... 14.186 Aircraft Type with intervention
.... 14.187 Altitude
.... 14.188 Altitude comparing intervention vs. comparator
.... 14.189 Altitude for enrolled group
.... 14.190 Altitude for screened group
.... 14.191 Altitude with comparator
.... 14.192 Altitude with intervention
.... 14.193 Analyzed Group in PARACHUTE Trial
.... 14.194 Anticoagulation for COVID-19 Combined RCTs in NEJM
.... 14.195 Baseline Characteristics Report for NCT03640312
.... 14.196 Baseline Characteristics Report for QUARTET Trial
.... 14.197 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.198 Baseline Measures List for PARACHUTE Trial
.... 14.199 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group
.... 14.200 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group
.... 14.201 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group
.... 14.202 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group
.... 14.203 BaselineVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.204 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
.... 14.205 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.206 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.207 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation
.... 14.208 Candesartan 8 mg once daily
.... 14.209 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.210 Change in Mean Diastolic Blood Pressure (NCT03640312)
.... 14.211 Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.212 Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.213 Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.214 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 14.215 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 14.216 Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312
.... 14.217 Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.218 Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.219 Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.220 Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.221 Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.222 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.223 Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.224 Citation for EBMonFHIR Implementation Guide
.... 14.225 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.226 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
.... 14.227 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.228 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z
.... 14.229 Comparative Evidence Report for QUARTET USA Trial
.... 14.230 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.231 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.232 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 14.233 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)
.... 14.234 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 14.235 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 14.236 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 14.237 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 14.238 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 14.239 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014
.... 14.240 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015
.... 14.241 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016
.... 14.242 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015
.... 14.243 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008
.... 14.244 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014
.... 14.245 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013
.... 14.246 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015
.... 14.247 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013
.... 14.248 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial
.... 14.249 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial
.... 14.250 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014
.... 14.251 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial
.... 14.252 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial
.... 14.253 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014
.... 14.254 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.255 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.256 ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.257 ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.258 ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
.... 14.259 ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 14.260 ComparatorDefinition: Obese patients ≥ 18 years old without bariatric surgery
.... 14.261 ComparatorDefinition: Standard care
.... 14.262 ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 14.263 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.264 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis
.... 14.265 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study
.... 14.266 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.267 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.268 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.269 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.270 Composite Rating of FOI 153881 for Project FOI 112280
.... 14.271 Computable_Publishing_LLC
.... 14.272 ConceptualCohortDefinition: At least 2 risk factors for stroke
.... 14.273 ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.274 ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.275 ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.276 ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.277 ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation
.... 14.278 ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity
.... 14.279 ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans
.... 14.280 ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59
.... 14.281 ConceptualCohortDefinition: Heart failure based on Phenotypes
.... 14.282 ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration
.... 14.283 ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria
.... 14.284 ConceptualCohortDefinition: Nonfatal myocardial infarction
.... 14.285 ConceptualCohortDefinition: Nonfatal stroke
.... 14.286 ConceptualCohortDefinition: Oxygen saturation < 96% on Boots Finger Pulse Oximeter
.... 14.287 ConceptualCohortDefinition: Oxygen saturation < 96% on Boots Finger Pulse Oximeter with Ranges
.... 14.288 ConceptualCohortDefinition: Proxy criteria for surgical candidates
.... 14.289 ConceptualCohortDefinition: Severe obesity
.... 14.290 ConceptualCohortDefinition: T1DM or T2DM
.... 14.291 ConceptualCohortDefinition: T1DM-specific criteria
.... 14.292 ConceptualCohortDefinition: T2DM-specific criteria
.... 14.293 ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years
.... 14.294 ConceptualCohortDefinition_Cardiovascular_event
.... 14.295 ConceptualComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.296 ConceptualComparatorDefinition: Usual-care pharmacologic thromboprophylaxis
.... 14.297 ConceptualExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.298 ConceptualExposureDefinition: Therapeutic-dose anticoagulation with heparin
.... 14.299 COVID_19PneumoniaHospitalizedAdult
.... 14.300 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.301 CTIS2024-516402-32-00 Eligibility Criteria
.... 14.302 CTIS2024-516402-32-00 Primary Outcome 1
.... 14.303 CTIS2024-516402-32-00 Secondary Outcome 1
.... 14.304 CTIS2024-516402-32-00 Secondary Outcome 2
.... 14.305 CTIS2024-516402-32-00 Secondary Outcome 3
.... 14.306 CTIS2024-516402-32-00 Secondary Outcome 4
.... 14.307 CTIS2024-516402-32-00 Secondary Outcome 5
.... 14.308 CTIS2024-516402-32-00 Secondary Outcome 6
.... 14.309 CTIS2024-516402-32-00 Secondary Outcome 7
.... 14.310 CTIS2024-516402-32-00 Secondary Outcome 8
.... 14.311 DatabaseCitation: Citation for FEvIR Platform
.... 14.312 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.313 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes
.... 14.314 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban
.... 14.315 Death or Major Traumatic Injury 30 days after Impact comparing intervention vs. comparator
.... 14.316 Death or Major Traumatic Injury 30 days after Impact with comparator
.... 14.317 Death or Major Traumatic Injury 30 days after Impact with intervention
.... 14.318 Death or Major Traumatic Injury on Impact comparing intervention vs. comparator
.... 14.319 declined randomization in PARACHUTE Study
.... 14.320 deemed unsuitable by investigator in PARACHUTE Trial
.... 14.321 Delany-Moretlwe 2022 clinical trial
.... 14.322 Diabetes treatment medication
.... 14.323 Diastolic blood pressure at 12 weeks
.... 14.324 DichotomousIntendedOutcome: Death or Major Traumatic Injury within 30 days
.... 14.325 Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU)
.... 14.326 Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
.... 14.327 Efficacy of Corticosteroids in COVID-19 Patients: A Systematic Review and Meta-Analysis
.... 14.328 Eligibility criteria for NMA_Diabetes
.... 14.329 Eligibility Criteria for QUARTET USA Trial
.... 14.330 Eli_Lilly_Japan_K_K
.... 14.331 Enrolled Group for QUARTET USA Trial
.... 14.332 Enrolled Group PARACHUTE Trial
.... 14.333 Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie
.... 14.334 Ethnic Group
.... 14.335 Ethnic Group with comparator
.... 14.336 Ethnic Group with intervention
.... 14.337 Evidence Based Medicine on FHIR Implementation Guide Code System
.... 14.338 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.339 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.340 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Control Group
.... 14.341 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Quadpill group
.... 14.342 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.343 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.344 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Control Group
.... 14.345 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.346 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.347 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.348 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 14.349 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.350 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.351 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.352 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Control Group
.... 14.353 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.354 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.355 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.356 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Control Group
.... 14.357 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.358 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.359 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.360 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 14.361 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.362 Evidence List: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)
.... 14.363 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.364 EvidenceReportSectionCode Value Set
.... 14.365 EvidenceReportSubject: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.366 EvidenceVariable Handling Extension Value Set
.... 14.367 EvidenceVariable: case_id
.... 14.368 EvidenceVariable: Patient id
.... 14.369 EvidenceVariable: Time of measurement
.... 14.370 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.371 Excluded from PARACHUTE Study
.... 14.372 ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort
.... 14.373 ExposureVariable: Age (as continuous variable)
.... 14.374 ExposureVariable: Body Mass Index (as continuous variable)
.... 14.375 ExposureVariable: pht013093.v1.p1 Age at diagnosis
.... 14.376 ExposureVariable: pht013093.v1.p1 RACE
.... 14.377 ExposureVariable: pht013093.v1.p1 SEX
.... 14.378 ExposureVariable: pht013093.v1.p1 SUBJECT_ID
.... 14.379 ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE
.... 14.380 ExposureVariable: pht013094.v1.p1 BODY_SITE
.... 14.381 ExposureVariable: pht013094.v1.p1 IS_TUMOR
.... 14.382 ExposureVariable: pht013094.v1.p1 SAMPLE_ID
.... 14.383 ExposureVariable: pht013094.v1.p1 SAMPLE_USE
.... 14.384 ExposureVariable: pht013094.v1.p1 Source_Type
.... 14.385 Family History of Parachute Use
.... 14.386 Family History of Parachute Use with comparator
.... 14.387 Family History of Parachute Use with intervention
.... 14.388 Frequent Flier
.... 14.389 Frequent Flier with comparator
.... 14.390 Frequent Flier with intervention
.... 14.391 GLP-1 RA Group in Adults with type 2 diabetes
.... 14.392 GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk
.... 14.393 Glucagon Hydrochloride Solution (Active Comparator)
.... 14.394 Glucagon Nasal Powder (Experimental)
.... 14.395 Group Randomized to Comparator (empty backpack) in PARACHUTE Trial
.... 14.396 Group Randomized to Intervention Group (parachute) in PARACHUTE Trial
.... 14.397 GroupAssignment: Bariatric Surgery vs. no bariatric surgery
.... 14.398 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.399 GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 14.400 GroupAssignment: GLP-1 RA vs. Standard care
.... 14.401 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo
.... 14.402 GroupAssignment: Jumping from aircraft with parachute vs. Jumping from aircraft with empty backpack
.... 14.403 GroupAssignment: Non Participants vs. Enrolled Participants
.... 14.404 GroupAssignment: Quadpill vs. Candesartan
.... 14.405 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment
.... 14.406 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone
.... 14.407 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment
.... 14.408 GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
.... 14.409 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis
.... 14.410 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.411 Health Survey Score Total
.... 14.412 Health Survey Score Total comparing intervention vs. comparator
.... 14.413 Health Survey Score Total with comparator
.... 14.414 Health Survey Score Total with intervention
.... 14.415 Health Survey Score-Mental Health Subscore
.... 14.416 Health Survey Score-Mental Health Subscore comparing intervention vs. comparator
.... 14.417 Health Survey Score-Mental Health Subscore with comparator
.... 14.418 Health Survey Score-Mental Health Subscore with intervention
.... 14.419 Health Survey Score-Physical Health Subscore
.... 14.420 Health Survey Score-Physical Health Subscore comparing intervention vs. comparator
.... 14.421 Health Survey Score-Physical Health Subscore with comparator
.... 14.422 Health Survey Score-Physical Health Subscore with intervention
.... 14.423 Health-related Quality of Life (NCT03640312)
.... 14.424 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)
.... 14.425 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312
.... 14.426 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 14.427 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)
.... 14.428 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312
.... 14.429 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 14.430 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.431 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.432 Height
.... 14.433 Height with comparator
.... 14.434 Height with intervention
.... 14.435 High Blood Pressure Medication Value Set
.... 14.436 History of Acrophobia
.... 14.437 History of Acrophobia with comparator
.... 14.438 History of Acrophobia with intervention
.... 14.439 History of Broken Bones
.... 14.440 History of Broken Bones with comparator
.... 14.441 History of Broken Bones with intervention
.... 14.442 History of Parachute Use
.... 14.443 History of Parachute Use with comparator
.... 14.444 History of Parachute Use with intervention
.... 14.445 Hypertension Control at 12 weeks
.... 14.446 ICD-10-GM Terminale Codes
.... 14.447 IGBJ Protocol Narrative 1.3
.... 14.448 IGBJ Protocol Narrative 2.1
.... 14.449 IGBJ Protocol Narrative 5.1
.... 14.450 IGBJ Protocol Narrative 9
.... 14.451 Injury Severity Score 30 days after Impact comparing intervention vs. comparator
.... 14.452 Injury Severity Score 30 days after Impact with comparator
.... 14.453 Injury Severity Score 30 days after Impact with intervention
.... 14.454 Injury Severity Score on Impact comparing intervention vs. comparator
.... 14.455 Injury Severity Score on Impact with comparator
.... 14.456 Injury Severity Score on Impact with intervention
.... 14.457 International vs Domestic Flight
.... 14.458 International vs Domestic Flight with comparator
.... 14.459 International vs Domestic Flight with intervention
.... 14.460 InterventionDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 14.461 InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
.... 14.462 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.463 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.464 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.465 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.466 Investigator
.... 14.467 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA
.... 14.468 IV remdesivir 200 mg then 100 mg/day for 9 days
.... 14.469 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.470 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.471 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.472 Jumping from aircraft with empty backpack
.... 14.473 Jumping from aircraft with parachute
.... 14.474 Justification for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.475 Justification for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.476 M11 IGBJ Protocol Example Eligibility Criteria
.... 14.477 M11 IGBJ Protocol Example for EBMonFHIR IG
.... 14.478 M11 Report Template Instructions
.... 14.479 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.480 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.481 MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.482 MAGIC-derived ComparatorOnlyEvidence: Body weight in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.483 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.484 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.485 MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.486 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.487 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.488 MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.489 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.490 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.491 MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.492 MAGIC-derived ComparatorOnlyEvidence: Heart failure in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.493 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.494 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.495 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.496 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.497 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.498 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.499 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.500 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.501 MAGIC-derived Evidence: All-cause mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.502 MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.503 MAGIC-derived Evidence: Body weight with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.504 MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.505 MAGIC-derived Evidence: Cardiovascular mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.506 MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.507 MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.508 MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.509 MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.510 MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.511 MAGIC-derived Evidence: Health-related quality of life with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.512 MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.513 MAGIC-derived Evidence: Heart failure with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.514 MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.515 MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.516 MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.517 MAGIC-derived Evidence: Nonfatal stroke with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.518 MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.519 MAGIC-derived Evidence: Serious hyperglycaemia with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.520 MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.521 MAGIC-derived Evidence: Severe gastrointestinal events with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.522 MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.523 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.524 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.525 MAGIC-derived InterventionOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.526 MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.527 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.528 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.529 MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.530 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.531 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.532 MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.533 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.534 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.535 MAGIC-derived InterventionOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.536 MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.537 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.538 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.539 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.540 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.541 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.542 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.543 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.544 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.545 Mean Change in Blood Urea Nitrogen (NCT03640312)
.... 14.546 Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312
.... 14.547 Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.548 Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.549 Mean Change in Serum Creatinine (NCT03640312)
.... 14.550 Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312
.... 14.551 Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.552 Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.553 Mean Change in Serum Potassium (NCT03640312)
.... 14.554 Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312
.... 14.555 Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.556 Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.557 Mean Change in Serum Sodium (NCT03640312)
.... 14.558 Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312
.... 14.559 Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.560 Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.561 Mean Diastolic Blood Pressure (NCT03640312)
.... 14.562 Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.563 Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.564 Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.565 Mean Systolic Blood Pressure (NCT03640312)
.... 14.566 Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.567 Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.568 Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.569 Median Age of Parachute Intervention Group
.... 14.570 Medication Adherence (NCT03640312)
.... 14.571 Medication Adherence at 12 weeks
.... 14.572 Medication Adherence at 12 weeks for Candesartan in NCT03640312
.... 14.573 Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.574 Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.575 MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 14.576 MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.577 MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs
.... 14.578 MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.579 Mortality at 14 days
.... 14.580 NCT03421379 Eligibility Criteria
.... 14.581 NCT03640312 Eligibility Criteria
.... 14.582 NetEffectContribution: Additional GI surgical procedure for Example for GIN 2022
.... 14.583 NetEffectContribution: All-cause mortality for Example for GIN 2022
.... 14.584 NetEffectContribution: New onset depression for Example for GIN 2022
.... 14.585 NetEffectContribution: Nonfatal myocardial infarction or stroke for Example for GIN 2022
.... 14.586 NetEffectContribution: Remission of diabetes for Example for GIN 2022
.... 14.587 NetEffectContribution: Treatment with opioids for Example for GIN 2022
.... 14.588 NetEffectContributionList: Bariatric Surgery Example for GIN 2022
.... 14.589 NetEffectContributions: Bariatric Surgery Example for GIN 2022
.... 14.590 NetEffectEstimate: Bariatric Surgery Example for GIN 2022
.... 14.591 NHANES LBDGLUSI Variable Definition Cohort Definition
.... 14.592 NHANES LBDGLUSI: Fasting Glucose (mmol/L)
.... 14.593 NHANES LBXGLU Variable Definition Cohort Definition
.... 14.594 NHANES LBXGLU: Fasting Glucose (mg/dL)
.... 14.595 NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary
.... 14.596 NHANES SEQN Respondent Sequence Number
.... 14.597 NHANES WTSAF2YR Variable Definition Cohort Definition
.... 14.598 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight
.... 14.599 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities
.... 14.600 NT-proBNP Study Data Dictionary
.... 14.601 Number of Patients Requiring Step up Treatment (NCT03640312)
.... 14.602 Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312
.... 14.603 Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.604 Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.605 Organ support-free days
.... 14.606 Outcome Importance Rating 100 of All-cause mortality
.... 14.607 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke
.... 14.608 Outcome Importance Rating 5 of New onset depression
.... 14.609 Outcome Importance Rating 5 of Remission of diabetes
.... 14.610 Outcome Importance Rating 5 of Treatment with opioids
.... 14.611 Outcome Importance Rating 8 of Additional GI surgical procedure
.... 14.612 Outcome Measure List for QUARTET USA Trial
.... 14.613 Outcome Measure Report for QUARTET USA Trial
.... 14.614 Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.615 Outcome Measures Report for NCT03640312
.... 14.616 Outcome Variables List for PARACHUTE Trial
.... 14.617 Outcome: Death or Major Traumatic Injury 30 days after Impact
.... 14.618 Outcome: Death or Major Traumatic Injury on Impact
.... 14.619 Outcome: Injury Severity Score 30 days after Impact
.... 14.620 Outcome: Injury Severity Score on Impact
.... 14.621 OutcomeDefinition: Injury Severity Score on Impact
.... 14.622 OutcomeDefinition: All-cause mortality
.... 14.623 OutcomeDefinition: All-cause mortality
.... 14.624 OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control
.... 14.625 OutcomeDefinition: Body weight
.... 14.626 OutcomeDefinition: Body weight
.... 14.627 OutcomeDefinition: Cardiovascular mortality
.... 14.628 OutcomeDefinition: Cardiovascular mortality
.... 14.629 OutcomeDefinition: Diabetes in remission
.... 14.630 OutcomeDefinition: Diabetic ketoacidosis
.... 14.631 OutcomeDefinition: End-stage kidney disease
.... 14.632 OutcomeDefinition: End-stage kidney disease
.... 14.633 OutcomeDefinition: Genital infection
.... 14.634 OutcomeDefinition: HbA1c at 12 months
.... 14.635 OutcomeDefinition: HbA1c at 24 months
.... 14.636 OutcomeDefinition: HbA1c at 36 months
.... 14.637 OutcomeDefinition: HbA1c at 6 months
.... 14.638 OutcomeDefinition: HbA1c at 60 months
.... 14.639 OutcomeDefinition: Health-related quality of life
.... 14.640 OutcomeDefinition: Health-related quality of life
.... 14.641 OutcomeDefinition: Heart failure
.... 14.642 OutcomeDefinition: Heart failure
.... 14.643 OutcomeDefinition: Mortality at 14 days
.... 14.644 OutcomeDefinition: New onset depression
.... 14.645 OutcomeDefinition: Nonfatal myocardial infarction
.... 14.646 OutcomeDefinition: Nonfatal myocardial infarction
.... 14.647 OutcomeDefinition: Nonfatal myocardial infarction or stroke
.... 14.648 OutcomeDefinition: Nonfatal stroke
.... 14.649 OutcomeDefinition: Nonfatal stroke
.... 14.650 OutcomeDefinition: Serious hyperglycaemia
.... 14.651 OutcomeDefinition: Serious hyperglycaemia
.... 14.652 OutcomeDefinition: Severe gastrointestinal events
.... 14.653 OutcomeDefinition: Severe gastrointestinal events
.... 14.654 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.655 OutcomeMeasureReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.656 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
.... 14.657 OutcomeVariable: HbA1c at 12 months
.... 14.658 OutcomeVariable: HbA1c at 24 months
.... 14.659 OutcomeVariable: HbA1c at 36 months
.... 14.660 OutcomeVariable: HbA1c at 6 months
.... 14.661 OutcomeVariable: HbA1c at 60 months
.... 14.662 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.663 OutcomeVariable: New onset depression
.... 14.664 OutcomeVariable: Nonfatal myocardial infarction or stroke
.... 14.665 OutcomeVariable: Remission of diabetes
.... 14.666 OutcomeVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.667 OutcomeVariable_Additional_GI_surgical_procedure
.... 14.668 OutcomeVariable_All_cause_mortality
.... 14.669 OutcomeVariable_Treatment_with_opioids
.... 14.670 PARACHUTE Trial baseline characteristics
.... 14.671 PARACHUTE Trial non participants
.... 14.672 PARACHUTE trial participant flow report
.... 14.673 PARACHUTE Trial Participants
.... 14.674 PARACHUTE Trial Participants assigned an empty backpack
.... 14.675 PARACHUTE trial participants assigned parachute
.... 14.676 PARACHUTE Trial Participants available for randomization
.... 14.677 PARACHUTE Trial Participants deemed unsuitable by investigator
.... 14.678 PARACHUTE Trial Participants randomized into groups
.... 14.679 PARACHUTE Trial Participants randomized into groups for screened group
.... 14.680 PARACHUTE Trial Participants randomized into groups with comparator
.... 14.681 PARACHUTE Trial Participants randomized into groups with intervention
.... 14.682 PARACHUTE Trial Participants that completed 30 day follow up
.... 14.683 PARACHUTE Trial Participants that completed 30 day follow up with comparator
.... 14.684 PARACHUTE Trial Participants that completed 30 day follow up with intervention
.... 14.685 PARACHUTE Trial Participants that completed jump and 5 minute follow-up
.... 14.686 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with comparator
.... 14.687 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with intervention
.... 14.688 PARACHUTE Trial Participants that declined randomization
.... 14.689 PARACHUTE Trial Participants with no contact at 30 days
.... 14.690 PARACHUTE Trial Participants with no contact at 30 days with comparator
.... 14.691 PARACHUTE Trial Participants with no contact at 30 days with intervention
.... 14.692 PARACHUTE Trial Results
.... 14.693 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 14.694 Parachute vs Empty Backpack in PARACHUTE Trial
.... 14.695 Participant Flow Report for NCT03640312
.... 14.696 Participant Flow Report for QUARTET USA Trial
.... 14.697 Participant Flow Variables List for PARACHUTE Trial
.... 14.698 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis
.... 14.699 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis
.... 14.700 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis
.... 14.701 ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis
.... 14.702 ParticipantFlowMeasure: Dropout due to stopping intervention
.... 14.703 ParticipantFlowMeasure: Exclusion from analysis
.... 14.704 ParticipantFlowMeasure: Inclusion in analysis
.... 14.705 Participants Excluded from PARACHUTE Study
.... 14.706 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill
.... 14.707 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill
.... 14.708 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 14.709 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379)
.... 14.710 Percentage of Participants With Potentially Related Adverse Events (NCT03640312)
.... 14.711 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312
.... 14.712 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.713 Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.714 Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312)
.... 14.715 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312
.... 14.716 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.717 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.718 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379)
.... 14.719 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 14.720 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 14.721 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 14.722 Placebo
.... 14.723 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.724 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.725 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
.... 14.726 Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312)
.... 14.727 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312
.... 14.728 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.729 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.730 Proportion of Patients With Hypertension Control (NCT03640312)
.... 14.731 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)
.... 14.732 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312
.... 14.733 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312
.... 14.734 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)
.... 14.735 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312
.... 14.736 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312
.... 14.737 Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.738 Quadpill once daily
.... 14.739 QUARTET USA Trial Control Group
.... 14.740 QUARTET USA Trial Quadpill group
.... 14.741 randomized into groups for PARACHUTE Trial
.... 14.742 Rate of Adverse Events of Special Interest (NCT03640312)
.... 14.743 Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312
.... 14.744 Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.745 Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.746 Rate of Death or Major Traumatic Injury on Impact with comparator
.... 14.747 Rate of Death or Major Traumatic Injury on Impact with intervention
.... 14.748 Reasons for exclusion from QUARTET USA Trial
.... 14.749 Recommendation Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17)
.... 14.750 Recommendation Justification Code System
.... 14.751 Recommendation Rating: ADA Obesity Management Recommendation 8.16
.... 14.752 Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.753 Recommendation: ADA Obesity Management Recommendation 8.16-adapted
.... 14.754 Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.755 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16)
.... 14.756 Remdesivir
.... 14.757 Remdesivir IV 200 mg once then 100 mg once daily for 9 days
.... 14.758 Results Section for NCT03421379
.... 14.759 Results Section for NCT03640312
.... 14.760 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.761 Risk of Bias Assessment of PARACHUTE trial
.... 14.762 Risk Of Bias Type Value Set
.... 14.763 Screened Group PARACHUTE Trial
.... 14.764 Search Strategy for NMA_Diabetes
.... 14.765 SearchResults: PubMed search for Wonder Woman
.... 14.766 SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review
.... 14.767 SearchStrategy: PubMed search for Wonder Woman
.... 14.768 Sex
.... 14.769 Sex with comparator
.... 14.770 Sex with intervention
.... 14.771 SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.772 SoaPlanDefinition: Follow-up assessment 3 months after study start
.... 14.773 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
.... 14.774 Spanish or English Value Set
.... 14.775 Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.776 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488
.... 14.777 StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial
.... 14.778 StudyEligibilityCriteria: Obese patients ≥ 18 years old
.... 14.779 StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 14.780 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study
.... 14.781 StudyGroup: Diabetes Surgery Study Trial Enrollment Group
.... 14.782 StudyGroup: Severely Obese Adults 2018 Norwegian Cohort
.... 14.783 StudyGroup_DIBASY_Trial_Enrollment_Group
.... 14.784 Summary of Findings - QUARTET USA Trial
.... 14.785 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 14.786 SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.787 SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.788 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 14.789 SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.790 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.791 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.792 Systolic blood pressure at 12 weeks
.... 14.793 Time to integration of results in a recommendation
.... 14.794 VariableDefinition: Comparator
.... 14.795 VariableDefinition: Condition(s)
.... 14.796 VariableDefinition: Date of birth
.... 14.797 VariableDefinition: Date of measurement
.... 14.798 VariableDefinition: Gender
.... 14.799 VariableDefinition: NTproBNP
.... 14.800 VariableDefinition: Unit
.... 14.801 Velocity
.... 14.802 Velocity comparing intervention vs. comparator
.... 14.803 Velocity for enrolled group
.... 14.804 Velocity for non participant group
.... 14.805 Velocity with comparator
.... 14.806 Velocity with intervention
.... 14.807 WebPageCitation: A HEvKA Update Summary
.... 14.808 Weight
.... 14.809 Weight with comparator
.... 14.810 Weight with intervention